Gilead's BIC LEN HIV Results Highlight Valuation Gap And Future Potential [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Gilead Sciences reported positive Phase 3 results for its BIC/LEN HIV regimen at CROI 2026. The ARTISTRY-1 and ARTISTRY-2 trials showed efficacy and safety in line with current complex and single tablet HIV therapies. BIC/LEN is a once daily single tablet option aimed at people living with HIV, including those currently on multi pill regimens. For investors watching Gilead Sciences, NasdaqGS:GILD, the BIC/LEN data adds a fresh clinical milestone to an already established HIV franchise. The company's shares recently traded at $143.93, with a 26.0% return over the past year and a very large 3 year gain of about 7x. Over 5 years, the stock shows a 180.1% return, which underlines how HIV research has remained central to the story. Short term returns have been softer, with a 3.4% decline over the past week and a 3.6% decline over the past month, while the stock is still up
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? [Yahoo! Finance]Yahoo! Finance
- Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (GILD) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $180.00 price target on the stock.MarketBeat
- ???????????????????? :???????????????2035????2388?2000????????????????????(CAGR)6.0%???????????? [CNET News]CNET News
- Is It Time To Reassess Gilead Sciences (GILD) After Its Strong Share Price Run [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- GILD's page on the SEC website